References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailIntensive and prolonged health promotion strategy may increase self-reported osteoporosis prevalence among postmenopausal women
Tellier, V; De Maeseneer, J; Cartier, P et al

in Annals of the Rheumatic Diseases (2000), 59(S1), 58

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
REGINSTER, Jean-Yves ULg; Minne, H. W.; Sorensen, O. H. et al

in Osteoporosis International (2000), 11(1), 83-91

The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with ... [more ▼]

The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease. [less ▲]

Detailed reference viewed: 20 (13 ULg)
Full Text
Peer Reviewed
See detailInterest of a simple pre-screening test for optimizing the cost/benefit value of bone densitometry
Ben Sedrine, Wafa ULg; Broers, Ph; Brands, G et al

in Osteoporosis International (2000), SS(S5), 13

Detailed reference viewed: 28 (5 ULg)
Full Text
Peer Reviewed
See detailA simple clinical tool to identify Asian women with osteoporosis
Ben Sedrine, Wafa ULg; Koh, L; Radican, L et al

in Osteoporosis International (2000), 11(S5), 9

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailThe simple calculated ostoporosis risk estimation (SCORE) does not allow to identify Belgian women with a high risk of osteoporosis
Ben Sedrine, Wafa ULg; Devogelaer, JP; Kaufman, JM et al

in Osteoporosis International (2000), 11(S2), 3

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fracture risk in elderly women with osteoporosis
McClung, M; Eastell, R; Bensen, W et al

in Osteoporosis International (2000), 11(S2), 207

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailEffect of raloxifene and alendronate on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis
Johnell, O; Lu, Y; Seeman, E et al

in Osteoporosis International (2000), 11(S2), 184

Detailed reference viewed: 5 (3 ULg)
Full Text
Peer Reviewed
See detailThe antioxidant properties of non stroidal anti-inflammatory drugs
Henrotin, Yves ULg; Mouithys-Mickalad, Ange ULg; Mathy-Hartert, M et al

in Osteoarthritis and Cartilage (2000), 8

Detailed reference viewed: 28 (1 ULg)
Full Text
Peer Reviewed
See detailEffects of antioxidants on interleukin-1β, nitric oxide and prostaglandin E2 production by human chondrocytes
Mathy-Hartert, M; Ayache, N; Boumediene, K et al

in Osteoarthritis and Cartilage (2000), 8

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailEffects of raloxifene on bone mineral density and biochemical markers of bone turnover in postmenopausal women with osteoporosis : 4-year results from the MORE trial
Delmas, PD; Ensrud, KE; Harper, K et al

in Journal of Bone and Mineral Research (2000), 15(S1), 556

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailThe effects of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis : 4-year results from the MORE trial
Eastell, R; Adachi, J; Harper, K et al

in Journal of Bone and Mineral Research (2000), 15(S1), 229

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate significantly reduces hip fracture risk in elderly women with osteoporosis
Bensen, W; Piette, F; Ettinger, M et al

in Journal of Bone and Mineral Research (2000), 15(S1), 226

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailRapid and consistent effect of risedronate on vertebral fracture risk reduction in elderly postmenopausal women
Greenwald, M; Fischer, M; Poiley, J et al

in Journal of Bone and Mineral Research (2000), 15(S1), 226

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailIpriflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women
Alexandersen, P; Toussaint, A; Reginster, Jean-Yves ULg et al

in Journal of Bone and Mineral Research (2000), 15(S1), 198

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailRapid and sustained effects of risedronate in reducting hip fracture risk in elderly women with osteoporis
Seeman, E; McClung, M; Zippel, H et al

in Journal of Bone and Mineral Research (2000), 15(S1), 149

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailFailure of ipriflavone to significantly reduce vertebral fracture rates and to increase bone mineral density in postmenopausal osteoporosis : the IMEFS study
Reginster, Jean-Yves ULg; Alexandersen, P; Devogelaer, JP et al

in Arthritis and Rheumatism (2000), 43(S1), 1898

Detailed reference viewed: 8 (1 ULg)